MedTrace Logo

Study of Oglemilast for the Treatment of Asthma

NCT00322686 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2012-03-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.

Conditions

Interventions

DRUG

Oglemilast

Oglemilast, 15mg oral administration, once per day and then dose-matched placebo

DRUG

Placebo then Oglemilast

Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322686 on ClinicalTrials.gov